ARX Inhibitors
ARX, a transcription factor belonging to the Aristaless-related homeobox gene family, plays a critical role in embryonic development, particularly in the formation and function of the central nervous system. Functionally, ARX is involved in the regulation of gene expression patterns essential for neuronal differentiation, migration, and specification of neuronal subtypes during brain development. Specifically, ARX regulates the expression of genes involved in GABAergic and cholinergic neurotransmitter systems, as well as genes encoding ion channels and synaptic proteins crucial for neuronal function. Through its transcriptional activity, ARX contributes to the establishment of neuronal circuitry and the formation of neural networks required for proper brain function. Dysregulation of ARX expression or function has been associated with various neurodevelopmental disorders, including X-linked lissencephaly with abnormal genitalia (XLAG) and West syndrome, highlighting its importance in neurodevelopmental processes.
Inhibition of ARX activity represents a strategy for modulating neuronal development and function, particularly in the context of neurodevelopmental disorders associated with ARX dysregulation. Mechanistically, inhibition of ARX may be achieved through various approaches, including interference with its DNA binding activity, disruption of protein-protein interactions, or modulation of its expression levels. Small molecule inhibitors targeting the DNA binding domain of ARX blocks its interaction with target gene promoters, thereby inhibiting transcriptional activation and altering gene expression patterns crucial for neuronal development. Additionally, strategies aimed at blocking protein-protein interactions essential for ARX function may impede its transcriptional activity and disrupt downstream signaling pathways involved in neurodevelopment. Understanding the mechanisms underlying ARX inhibition provides insights into the regulation of neuronal development and offers avenues for intervention in neurodevelopmental disorders characterized by ARX dysfunction.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Amiloride | 2609-46-3 | sc-337527 | 1 g | $296.00 | 7 | |
Amiloride, a sodium channel blocker, indirectly inhibits ARX by influencing cellular ion homeostasis. By blocking sodium channels, Amiloride disrupts the ionic balance within cells, affecting downstream signaling pathways that modulate ARX activity. The altered ion homeostasis can lead to changes in cellular processes related to ARX, highlighting the indirect inhibition of ARX by Amiloride through ion channel modulation. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin, a phosphoinositide 3-kinase (PI3K) inhibitor, indirectly inhibits ARX by disrupting the PI3K/Akt signaling pathway. The inhibition of PI3K by Wortmannin leads to decreased Akt activation, which is involved in the regulation of ARX. The suppression of PI3K/Akt signaling results in the indirect inhibition of ARX, illustrating the intricate cross-talk between PI3K/Akt signaling and ARX regulatory pathways. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
SB431542, a transforming growth factor-beta (TGF-β) receptor inhibitor, indirectly inhibits ARX by targeting TGF-β signaling. ARX is influenced by TGF-β-dependent pathways, and the inhibition of TGF-β receptors by SB431542 disrupts these signaling cascades, leading to the indirect inhibition of ARX. This highlights the regulatory role of TGF-β signaling in modulating ARX activity, and SB431542 serves as an indirect inhibitor through interference with this specific pathway. | ||||||
NSC 23766 | 733767-34-5 | sc-204823 sc-204823A | 10 mg 50 mg | $151.00 $609.00 | 75 | |
NSC23766, a Rac1 inhibitor, indirectly inhibits ARX by disrupting Rac1-dependent signaling pathways. ARX is known to be modulated by Rac1 activity, and the inhibition of Rac1 by NSC23766 hinders the activation of ARX through this specific pathway. The blockade of Rac1 signaling results in the indirect inhibition of ARX, emphasizing the role of small GTPases like Rac1 in regulating ARX function. | ||||||
GSK-3 Inhibitor XVI | 252917-06-9 | sc-221691 sc-221691A | 5 mg 25 mg | $180.00 $610.00 | 4 | |
GSK-3 Inhibitor XVI (CHIR-99021), a glycogen synthase kinase-3 (GSK-3) inhibitor, indirectly inhibits ARX by preventing GSK-3-mediated phosphorylation. The inhibition of GSK-3 by CHIR-99021 results in the stabilization and inhibition of ARX through decreased degradation. CHIR-99021 provides a specific mechanism for the indirect inhibition of ARX through the modulation of GSK-3-dependent pathways, highlighting the regulatory role of kinases in governing ARX stability and activity. | ||||||
PIK-75, hydrochloride | 372196-77-5 | sc-296089 sc-296089A | 1 mg 5 mg | $29.00 $124.00 | ||
PIK-75, a phosphoinositide 3-kinase (PI3K) inhibitor, indirectly inhibits ARX by disrupting the PI3K/Akt signaling pathway. Similar to Wortmannin, PIK-75 inhibits PI3K, leading to decreased Akt activation, which modulates ARX activity. The suppression of PI3K/Akt signaling results in the indirect inhibition of ARX, emphasizing the significance of the PI3K/Akt pathway in ARX regulation and the utility of PIK-75 as an indirect inhibitor. | ||||||
AZD5363 | 1143532-39-1 | sc-503190 | 5 mg | $309.00 | ||
AZD5363, an Akt kinase inhibitor, indirectly inhibits ARX by targeting the Akt signaling pathway. ARX is regulated by Akt-dependent phosphorylation, and the inhibition of Akt by AZD5363 disrupts this specific pathway, leading to the indirect inhibition of ARX. This highlights the significance of Akt-mediated signaling in ARX regulation, and AZD5363 serves as an indirect inhibitor by modulating this particular pathway influencing ARX activity. | ||||||
GW 5074 | 220904-83-6 | sc-200639 sc-200639A | 5 mg 25 mg | $106.00 $417.00 | 10 | |
GW5074, a c-Raf inhibitor targeting the MAPK/ERK pathway, indirectly inhibits ARX by disrupting the MAPK signaling cascade. ARX is modulated by ERK-dependent phosphorylation, and the inhibition of this pathway by GW5074 results in the indirect inhibition of ARX. This underscores the significance of MAPK/ERK signaling in ARX regulation, and GW5074 serves as an indirect inhibitor through interference with this specific pathway influencing ARX activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125, a JNK inhibitor, indirectly inhibits ARX by disrupting the JNK signaling pathway. ARX is influenced by JNK-dependent phosphorylation, and the inhibition of JNK by SP600125 results in the indirect inhibition of ARX. This emphasizes the significance of JNK signaling in ARX regulation, and SP600125 serves as an indirect inhibitor through interference with this specific pathway influencing ARX activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580, a p38 MAPK inhibitor, indirectly inhibits ARX by disrupting the p38 MAPK signaling pathway. ARX is modulated by p38 MAPK-dependent phosphorylation, and the inhibition of this pathway by SB203580 results in the indirect inhibition of ARX. This highlights the significance of p38 MAPK signaling in ARX regulation, and SB203580 serves as an indirect inhibitor through interference with this specific pathway influencing ARX activity. | ||||||